Background : Despite substantial progress, the treatment of acute myeloid leukemia(AML) has produced complete remission in 60-80% of patients receiving induction chemotherapy, and median remission duration is about 12 months and only 20% to 35% of patients undergoing consolidation chemotherapy achieve long-term disease-free survival(DFS). We evaluated the long-term outcome of AML patients treated with doxorubicin/Ara-C/VP-16(DAV) induction chemotherapy and consolidation/intensification therapy. Method : Induction therapy : From January 1986 to December 1991, twenty three patients with previously untreated acute myelogenous leukemia received a course of 45mg/㎡ doxorubicin daily intravenously for three consecutive days with Ara-C at 100mg/㎡ by continuous intravenous infusion for eight consecutive days and VP-16 at 100mg/㎡ daily intravenously for three consecutive days. A second course of treatment was started if leukemia persisted on 22 days after treatment. Post-remission therapy : Three to six cycles were given at three or four months interval with Ara-C/doxorubicin/VP-16 regimen or other therapy. Results : Twenty two pateints were evaluable and complete remission was achieved in 16 of 22(73%). Median duration of complete remission was 8 months. The relapse rate was 81% and 63% relapsed in first year. 4-year survival rate of patients entering complete remission(n=16) was 19% and median survival duration was 14.5 months. The postremission chemotherapy was the only significant prognostic factor influencing long term disease free survival. No significant correlation was observed between the probability of survival and age (40＜ or ＞40), sex, FAR subgroup, and leukocyte count at diagnosis. The median survival duration were 21 months and 12.5 months for patients who received, or not received postremission chemotherapy respectively(P=0.035). Conclusion : Our results show that DAV combination chemotherapy is a useful therapeutic regimen in remission induction and postremission chemotherapy offering survival advantage in patients with AML entering complete remission.